These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The problem with glycopeptides. Gould IM Int J Antimicrob Agents; 2007 Jul; 30(1):1-3. PubMed ID: 17507206 [No Abstract] [Full Text] [Related]
6. [Is the vancomycin resistance of Staphylococcus aureus left unnoticed?]. Vuento R Duodecim; 1999; 115(19):2045-7. PubMed ID: 11941798 [No Abstract] [Full Text] [Related]
7. Evaluation of spontaneous resistance to glycopeptide antibiotics in staphylococcal populations. Biavasco F; Montanari MP; Facinelli B; Varaldo PE J Chemother; 1989 Jul; 1(4 Suppl):389-90. PubMed ID: 16312453 [No Abstract] [Full Text] [Related]
8. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Whitener CJ; Park SY; Browne FA; Parent LJ; Julian K; Bozdogan B; Appelbaum PC; Chaitram J; Weigel LM; Jernigan J; McDougal LK; Tenover FC; Fridkin SK Clin Infect Dis; 2004 Apr; 38(8):1049-55. PubMed ID: 15095205 [TBL] [Abstract][Full Text] [Related]
9. Coexistence of vancomycin-resistant enterococci and Staphylococcus aureus in the intestinal tracts of hospitalized patients. Ray AJ; Pultz NJ; Bhalla A; Aron DC; Donskey CJ Clin Infect Dis; 2003 Oct; 37(7):875-81. PubMed ID: 13130397 [TBL] [Abstract][Full Text] [Related]
10. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Sader HS; Jones RN Clin Infect Dis; 2006 Sep; 43(6):798-9; author reply 799-800. PubMed ID: 16912964 [No Abstract] [Full Text] [Related]
11. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. Mariani PG; Sader HS; Jones RN J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029 [No Abstract] [Full Text] [Related]
12. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Julian K; Kosowska-Shick K; Whitener C; Roos M; Labischinski H; Rubio A; Parent L; Ednie L; Koeth L; Bogdanovich T; Appelbaum PC Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372 [TBL] [Abstract][Full Text] [Related]
14. Nosocomial methicillin--resistant Staphylococcus aureus with reduced susceptibility to vancomycin. Bhat G; Kamath S; Hussain A Indian J Pathol Microbiol; 2006 Apr; 49(2):311-2. PubMed ID: 16933753 [No Abstract] [Full Text] [Related]
15. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222 [TBL] [Abstract][Full Text] [Related]
16. Update on emerging infections: news from the Centers for Disease Control and Prevention. Moran GJ; Mount J Ann Emerg Med; 2003 Jan; 41(1):148-51. PubMed ID: 12514697 [No Abstract] [Full Text] [Related]
18. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Tenover FC; Moellering RC Clin Infect Dis; 2007 May; 44(9):1208-15. PubMed ID: 17407040 [TBL] [Abstract][Full Text] [Related]
19. [Conjugative transfer of glycopeptide and macrolide resistant genes among Enterococci and from Enterococcus faecalis to Staphylococcus aureus]. Młynarczyk A; Młynarczyk G; Łuczak M Med Dosw Mikrobiol; 2002; 54(1):21-8. PubMed ID: 12185680 [TBL] [Abstract][Full Text] [Related]
20. Staphylococcus aureus with reduced susceptibility to vancomycin in a dialysis graft. Perla RJ; Knutson EL; Fontana JL Clin Infect Dis; 2005 Aug; 41(4):566-7. PubMed ID: 16028171 [No Abstract] [Full Text] [Related] [Next] [New Search]